Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Physicians may need to dig deeper when treating HIV-related lymphomas

07.12.2004


USC study finds differences in survival according to lymphoma type in post-HAART era

When it comes to treating HIV-positive patients with blood cancers, not all lymphomas are created equal, according to hematologists from the University of Southern California. Although physicians have treated all types of lymphomas in HIV/AIDS patients with the same drug regimens, researchers from the USC/Norris Comprehensive Cancer Center and Hospital say the drugs are significantly more effective in patients with diffuse large-cell lymphoma, or DLCL, than in patients with small non-cleaved, or SNC, lymphoma. The findings, reported at the 46th Annual Meeting of the American Society of Hematology, suggest that researchers rethink the practice of using the same uniform treatment for everyone with AIDS-related lymphomas.

"Lymphoma is not one disease, but rather represents a group of over 30 different entities. Even lymphomas that were thought to be quite uniform and homogeneous are now recognized as being made up of different variations or sub-types. It will be important for scientists and physicians to recognize these various types, since optimal therapy in the future will probably differ for these sub-types of disease," says senior author Alexandra M. Levine, M.D., Distinguished Professor of Medicine, chief of hematology at the Keck School of Medicine of USC and medical director of the USC/Norris Cancer Hospital.



The USC hematologists reviewed records of more than 350 patients with the AIDS-related lymphomas treated at USC/Norris between 1982 and early 2004; 135 patients had SNC and 227 patients had DLCL.

The researchers looked at cases occurring before the advent of highly active antiretroviral therapy, or HAART, in 1996, as well as after the introduction of the successful anti-HIV therapy. They saw 117 SNC cases and 143 DLCL cases before HAART, and 18 SNC and 84 DLCL cases after HAART.

Throughout the period, all lymphoma patients were treated for their cancers with one of two equivalent, common chemotherapy combinations: cyclophosphamide, vincristine, adriamycin and prednisone; or methotrexate, bleomycin, adriamycin, cyclophosphamide, vincristine and dexamethasone.

USC/Norris researchers found that before HAART, overall survival of SNC and DLCL patients was about the same-about six or seven months. But after HAART, patients with DLCL began living significantly longer. DLCL patients’ average survival time after HAART’s 1996 introduction was 38 months-more than six times as long as SNC patients’ average survival time of 5.6 months.

The researchers also found that SNC patients were more likely than DLCL patients to have secondary cancer in their bone marrow, liver and kidneys. "Prior to the availability of effective treatment against HIV, patients with AIDS-related lymphoma often died of serious infections before they could receive adequate or optimal chemotherapy; the survival of these patients was quite short, in the range of only six months," Levine says. "Importantly, effective anti-HIV treatment has now allowed these patients to receive chemotherapy, and to benefit from it.

"However, our study has shown that not all types of lymphoma are the same, and different treatments will be required to achieve optimal results in these individuals. We expect that our study will eventually serve to change the way in which patients with AIDS-related Burkitt lymphoma are treated."

Sarah Huoh | EurekAlert!
Further information:
http://www.usc.edu

More articles from Health and Medicine:

nachricht Millions through license revenues
27.04.2017 | Rheinische Friedrich-Wilhelms-Universität Bonn

nachricht New High-Performance Center Translational Medical Engineering
26.04.2017 | Fraunhofer ITEM

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Making lightweight construction suitable for series production

More and more automobile companies are focusing on body parts made of carbon fiber reinforced plastics (CFRP). However, manufacturing and repair costs must be further reduced in order to make CFRP more economical in use. Together with the Volkswagen AG and five other partners in the project HolQueSt 3D, the Laser Zentrum Hannover e.V. (LZH) has developed laser processes for the automatic trimming, drilling and repair of three-dimensional components.

Automated manufacturing processes are the basis for ultimately establishing the series production of CFRP components. In the project HolQueSt 3D, the LZH has...

Im Focus: Wonder material? Novel nanotube structure strengthens thin films for flexible electronics

Reflecting the structure of composites found in nature and the ancient world, researchers at the University of Illinois at Urbana-Champaign have synthesized thin carbon nanotube (CNT) textiles that exhibit both high electrical conductivity and a level of toughness that is about fifty times higher than copper films, currently used in electronics.

"The structural robustness of thin metal films has significant importance for the reliable operation of smart skin and flexible electronics including...

Im Focus: Deep inside Galaxy M87

The nearby, giant radio galaxy M87 hosts a supermassive black hole (BH) and is well-known for its bright jet dominating the spectrum over ten orders of magnitude in frequency. Due to its proximity, jet prominence, and the large black hole mass, M87 is the best laboratory for investigating the formation, acceleration, and collimation of relativistic jets. A research team led by Silke Britzen from the Max Planck Institute for Radio Astronomy in Bonn, Germany, has found strong indication for turbulent processes connecting the accretion disk and the jet of that galaxy providing insights into the longstanding problem of the origin of astrophysical jets.

Supermassive black holes form some of the most enigmatic phenomena in astrophysics. Their enormous energy output is supposed to be generated by the...

Im Focus: A Quantum Low Pass for Photons

Physicists in Garching observe novel quantum effect that limits the number of emitted photons.

The probability to find a certain number of photons inside a laser pulse usually corresponds to a classical distribution of independent events, the so-called...

Im Focus: Microprocessors based on a layer of just three atoms

Microprocessors based on atomically thin materials hold the promise of the evolution of traditional processors as well as new applications in the field of flexible electronics. Now, a TU Wien research team led by Thomas Müller has made a breakthrough in this field as part of an ongoing research project.

Two-dimensional materials, or 2D materials for short, are extremely versatile, although – or often more precisely because – they are made up of just one or a...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

Fighting drug resistant tuberculosis – InfectoGnostics meets MYCO-NET² partners in Peru

28.04.2017 | Event News

Expert meeting “Health Business Connect” will connect international medical technology companies

20.04.2017 | Event News

Wenn der Computer das Gehirn austrickst

18.04.2017 | Event News

 
Latest News

Wireless power can drive tiny electronic devices in the GI tract

28.04.2017 | Medical Engineering

Ice cave in Transylvania yields window into region's past

28.04.2017 | Earth Sciences

Nose2Brain – Better Therapy for Multiple Sclerosis

28.04.2017 | Life Sciences

VideoLinks
B2B-VideoLinks
More VideoLinks >>>